December 12, 2025 — KFF Health News
When she was 18, Dr. Su Wang learned she had chronic hepatitis B after a blood donation, an infection she likely acquired from a household member decades earlier. Wang, now medical director for viral hepatitis programs at RWJBarnabas Health in New Jersey, says her experience illustrates how easily hepatitis B spreads within families and why early vaccination mattered.
On Dec. 5, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted 8–3 to end the longstanding U.S. recommendation that all newborns receive a hepatitis B vaccine dose shortly after birth. The committee, whose members were appointed by Health and Human Services Secretary Robert F. Kennedy Jr., adopted a policy that ties immediate newborn vaccination to maternal test results: infants of mothers who test positive for hepatitis B will continue to receive the birth dose and hepatitis B immune globulin when indicated, while parents of other newborns may choose to delay the first vaccine until two months of age.
ACIP members framed the change as reducing unnecessary interventions, aligning vaccination timing with maternal screening, and giving parents more control. Supporters called it an expansion of parental choice rather than a response to falling disease rates.
Many clinicians and public-health experts disagree, arguing the shift risks reversing decades of progress against a virus that still infects as many as 2.4 million Americans and contributes to tens of thousands of deaths each year. They point to historical lessons showing that risk-based approaches miss many infections and warned that moving away from a universal birth dose could recreate past failures.
Testing limitations are central to the debate. Pregnant women who acquire hepatitis B late in pregnancy may test negative at routine screening because the surface antigen has not yet become detectable, and false negatives do occur. ACIP acknowledges that hospitals should give the vaccine within 12 hours if a mother’s status is unknown at delivery and add immune globulin for certain high-risk situations, but clinicians say real-world systems often break down: lab results can be delayed or misplaced, pharmacy deliveries slowed, and documentation lost. Each additional step in the screening-and-deliver process increases opportunities for failures that could leave infants unprotected.
Some committee members proposed further changes, such as forgoing the third hepatitis B shot if antibody testing after the second dose shows high levels, and encouraging post-vaccination serology with insurer coverage. Several specialists warn the evidence does not support dropping doses: only a minority of infants achieve robust antibody levels after a single shot, and multiple doses are needed for durable protection.
Hepatitis B is unusually infectious among bloodborne pathogens. It can survive on household items like toothbrushes and razors for days and spread through common family contact, open sores, or small blood exposures as well as from mother to child. In the 1980s, many childhood infections stemmed from household rather than maternal transmission, which was a key reason health officials moved to a universal birth dose policy in 1991.
The impact of that policy was dramatic. Since routine newborn vaccination began, pediatric hepatitis B infections in the U.S. have dropped by more than 99 percent. A 2024 CDC analysis estimated the current schedule prevented over 6 million hepatitis B infections and nearly 1 million hospitalizations. Vaccinating at birth protects infants from early infection and from liver failure and cancer that can develop decades later, meaning the consequences of policy changes may not become apparent for 20 to 30 years.
Independent reviews raise alarms about the new guidance. The Vaccine Integrity Project evaluated more than 400 studies and reports and concluded that delaying the birth dose would reduce infant protection and increase avoidable hepatitis B infections, undermining years of progress. Some researchers estimate that moving the first dose to two months could lead to more than 1,400 preventable infections and roughly 300 additional liver cancer cases each year.
Critics also emphasize equity concerns. Opt-in or delayed strategies tend to lower vaccination coverage, especially among groups at higher risk: people who miss prenatal care or testing, those with undiagnosed infections, and families with gaps in hospital follow-through. Immigrant communities from regions where hepatitis B is endemic are particularly vulnerable to being left unprotected when policies rely on testing and individual choice rather than routine administration.
The U.S. will now be the only country to abandon a universal hepatitis B birth-dose recommendation, a fact some public-health experts say could lead to international divergence in pediatric vaccine policy and undermines a long-standing preventive strategy.
Voices with lived experience underscore what is at stake. Dr. Trieu Pham, born in Vietnam in 1976, believes he was infected at birth, developed cirrhosis by age 40, and eventually required a liver transplant. His children, vaccinated within hours of birth, are free of hepatitis B, he says — illustrating the protection that immediate neonatal vaccination can provide.
Supporters of the ACIP decision maintain it promotes parental autonomy and aligns vaccination with current screening practices. Opponents warn it weakens a proven public-health safeguard, may reduce coverage among those most at risk, and could presage broader changes to the childhood vaccine schedule. The Department of Health and Human Services said ACIP reviews evidence and issues recommendations intended to protect children, while researchers and clinicians call for careful monitoring and measures to prevent any increase in preventable hepatitis B infections.
KFF Health News is a national newsroom producing in-depth reporting on health issues and is one of the primary programs of KFF, the independent source for health policy analysis and polling.